Lista de obras -

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

artículo científico publicado en 2015

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

artículo científico publicado en 2010

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma ⬇️

artículo científico publicado el 27 de abril de 2012

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.

artículo científico publicado en 2013

Assessment of multimodality therapy use for extremity sarcoma in the United States

artículo científico publicado en 2013

Bone cancer

artículo científico publicado en 2013

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

artículo científico publicado en 2013

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

artículo científico publicado en 2017

Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study

artículo científico publicado en 2014

Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy

artículo científico publicado en 2013

Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received ca

artículo científico publicado en 2008

Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma

artículo científico publicado en 2014

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

scientific article published on August 2009

Head and neck cancer: changing epidemiology and public health implications

artículo científico publicado el 1 de septiembre de 2010

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

artículo científico publicado en 2006

Malignancies of the head and neck: the role for molecular targeted agents

artículo científico publicado en 2007

Management of Neuroendocrine Tumors of Unknown Origin ⬇️

artículo científico publicado el 1 de diciembre de 2011

NCCN Clinical Practice Guidelines Occult primary

artículo científico publicado en 2011

NCCN Guidelines Insights: Bone Cancer, Version 2.2017.

artículo científico publicado en 2017

Nasopharyngeal carcinoma: current management, future directions and dental implications

artículo científico publicado en 2007

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) ⬇️

artículo científico publicado el 18 de enero de 2012

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma ⬇️

artículo científico publicado el 11 de agosto de 2011

New therapeutic options in gastrointestinal stromal tumors

artículo científico publicado en 2008

Occult primary

artículo científico publicado en 2008

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

artículo científico publicado en 2016

Olaratumab for advanced soft tissue sarcoma

artículo científico

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer

artículo científico publicado en 2014

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

artículo científico publicado en 2016

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck ⬇️

artículo científico publicado el 17 de abril de 2012

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

artículo científico publicado en 2014

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib

artículo científico

Promising New Molecular Targeted Therapies in Head and Neck Cancer ⬇️

artículo científico publicado el 1 de marzo de 2013

Promising newer molecular-targeted therapies in head and neck cancer

artículo científico publicado en 2008

Recent advances in the treatment of oligodendrogliomas

artículo científico publicado en 2006

Salivary gland malignancies: the role for chemotherapy and molecular targeted agents

artículo científico publicado en 2008

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

artículo científico publicado en 2016

Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies

artículo científico publicado en 2017

Targeted therapies in advanced differentiated thyroid cancer

artículo científico

Targeted therapies in bone sarcomas: current approach and future directions ⬇️

artículo científico publicado el 22 de abril de 2011

Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas

artículo científico

Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib

artículo científico publicado en 2014

The role of inhibitors of the epidermal growth factor in management of head and neck cancer.

artículo científico publicado en 2008

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

artículo científico publicado en 2016

Treatment of multiple keratoacanthomas with erlotinib

artículo científico publicado en 2010

Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor

artículo científico publicado en 2014

Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma

artículo científico publicado en 2013

Lista de obras de

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma ⬇️

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.

Assessment of multimodality therapy use for extremity sarcoma in the United States

Bone cancer

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study

Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy

Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received ca

Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

Head and neck cancer: changing epidemiology and public health implications

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

Malignancies of the head and neck: the role for molecular targeted agents

Management of Neuroendocrine Tumors of Unknown Origin ⬇️

NCCN Clinical Practice Guidelines Occult primary

NCCN Guidelines Insights: Bone Cancer, Version 2.2017.

Nasopharyngeal carcinoma: current management, future directions and dental implications

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) ⬇️

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma ⬇️

New therapeutic options in gastrointestinal stromal tumors

Occult primary

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Olaratumab for advanced soft tissue sarcoma

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck ⬇️

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib

Promising New Molecular Targeted Therapies in Head and Neck Cancer ⬇️

Promising newer molecular-targeted therapies in head and neck cancer

Recent advances in the treatment of oligodendrogliomas

Salivary gland malignancies: the role for chemotherapy and molecular targeted agents

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies

Targeted therapies in advanced differentiated thyroid cancer

Targeted therapies in bone sarcomas: current approach and future directions ⬇️

Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas

Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib

The role of inhibitors of the epidermal growth factor in management of head and neck cancer.

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Treatment of multiple keratoacanthomas with erlotinib

Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor

Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma